DiFUSION to mitigate SSIs that affect an estimated 780,000 patients in the United States each yearAUSTIN, Texas – January 6, 2009 – (HSMN NewsFeed) - DiFUSION Technologies, Inc., a medical device company targeting the orthopaedic market, today announced its corporate launch. The company will focus on reducing the rising incidence of Surgical Site Infections (SSIs) in spinal surgeries.
“In large studies, five out of 100 spine cases result in SSIs often leading to second surgeries that are extremely costly and difficult for the patient,” said Dr. Matthew Geck, founder and board member of DiFUSION and leading orthopaedic surgeon in Austin, Texas. “DiFUSION will release a medical device in 2009 capable of killing 650 types of bacteria including antibiotic-resistant bacteria such as MRSA (also known as “Superbugs”) in the local surgical wound for up to four weeks following surgery.”
Full text >>
Sunday, January 11, 2009
DiFUSION Technologies Announces Company Launch Focused on Surgical Site Infections (SSIs)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment